UNI-PHARMA SA, a pharmaceutical company of the Tsetis Pharmaceutical Group of companies, won an important distinction, which captures its developmental and economic sign in the country's modern business and industrial production.

For one more year, on December 19, 2023, UNI-PHARMA SA emerged as a true industry leader, an ICAP assessment, receiving the ICAP TRUE LEADER title. In particular,

UNI-PHARMA was evaluated with this title, as: Included in the 500 most profitable Companies or 200 most profitable Groups for 2022 • It is among the 500 Companies or 150 Groups with the largest number of staff and having increased its staff from 2021 to 2022 • Ranked at the top of your Industry, based on Turnover • Has a high ICAP CRIF Credit Score.

The distinction was received by Mr. Athanasios Archontikis, Vice-Chairman of the Board of Directors of UNI-PHARMA SA.